London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting - very quick summary based on my understanding of each abstract. Purely IMO of course and I'm sure others will explain in more detail :)
A046 - relates to glycan mAB FG2811 and shows that it can activate TSCMs (stem memory T cells) with the potential to use them to create TCR/CAR T therapies
A185 - seems to be a summary of Modi1's MOA
A201 - GRP78 is a heat shock protein which is linked to autophagy and highly expressed in tumours. Citrullinated GRP78 is a potential target for Moditope - is this Modi3?
A212 - relates to Moditope. Blood from cancer patients and healthy volunteers was cultured with citrullinated/homocitrullinated peptides. Difference between the 2 groups suggests regulatory T cells (Tregs) may suppress immune response in some cancer patients - may need to be inhibited.
B203 - Modi2 and homocitrullination. Worth noting the role of MDSCs (myeloid derived suppressor cells) - highly immunosuppressive cells that are associated with a very poor prognosis and 'cold tumours'. The beauty of Modi2 is that these cells express MPO which generates Isocyanic acid which diffuses into the tumour and drives homocitrullination. So Moditope cleverly exploits MDSCs.
B223 - use of PEP-FOLD3 software which uses algos to screen and select epitopes for Moditope
A185 is interesting as is about the adjuvant of ISA's, Melief also in attendance at CICON19 ' Linking the TLR2 agonists to the peptides allowed the vaccine dose to be reduced 10-100 fold without loss of anti-tumor activity. These studies suggest that low dose of citrullinated peptides linked to TLR2 ligand should be rapidly translated to the clinic for the treatment of cancer. Furthermore, ovarian cancer patients show a CD4 proliferative response to one or more of the citrullinated peptides which is similar to that in healthy donors. These results suggest that Modi-1 could be an effective vaccine for ovarian cancer patients.'
Oh nice, the titles are out, that is a whole lot of science there the understanding of moditope, in particular, grows and grows and all to be presented right under Sahin and Mellman's noses by the talents of team scancell science.... I too am not sure we will get an RNS for the event however with so many new abstracts to be presented by not just Lindy it is possible... as I think we all agree 6 abstracts is impressive .... As for what may come from of it well that is down to who is paying attention :) if Sahin sees Mellman make a b line for Lindy and gets all jealous things we want to happen could get a move on lol
I peeped at the 'Abstracts' - there's a stunning amount of research and many contributors to each paper. Some of Scancell's Abstracts have been selected for 'Poster Sessions'. Really good to see not only new Scancell names but also 'outside' contributors in the big 6 . . . .
Under Prof. Lindy, 6 abstracts are listed, I guess that confirms Scancell's total.
A046 / An ultraspecific monoclonal antibody recognises a novel marker on stem memory T cells and induce cell proliferation and differentiation in vitro and in vivo
A185 / Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells
A201 / Citrullinated glucose-regulated protein 78 is a can-didate target for cancer immunotherapy
A212 / Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized
B203 / Carbamylation of lysine residues mediated by myeloid derived suppressor cells in the tumor environ-ment make excellent targets for CD4 T cell mediated can-cer immunotherapy
B223 / Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms
I thought B223 most interesting so let's see if that helps our progress. An impressive 'Meet' indeed but WTP, I'm not expecting any commercial news coming or an RNS but you never know.
BioNTech have done well to get one session 'Chair' in place and 3 actual 'Presentations' . . . I'm surprised that Prof. Lindy is not presenting I suppose - she certainly has enough to talk about and a few drums to bang.
Thank you for the reminder WTP and the link C7. Also, in the Program :-
Session 4: Immunotherapies, Non-Cell-Based Session Chairperson: Ira Mellman 11:00 am - 11:25 am Mechanistic basis of cancer immunotherapy: checkpoints at 10. Ira Mellman, Genentech, San Francisco, California 11:25 am - 11:50 am Title not available. Ugur Sahin, BioNTech, Mainz, Germany
Session 8: Vaccination Strategies Session Chairperson: Özlem Türeci 11:25 am - 11:50 am Cancer vaccines & combination with “standard of care” therapies. Sebastian Kreiter, BioNTech AG, Mainz, Germany 11:50 am - 12:15 pm Title not available. Özlem Türeci, BioNTech AG, Mainz, Germany
I wonder why 'Title not available' in the case of Ugur Sahin and Ozlem Tureci. Other familiar names - Cornelis J M Melief, Leiden Uni and Jennifer Wargo, M D Anderson.
Wow, can see another - Katherine Cook... so that is at least 6 abstracts.. I do not think we have ever done an event like this before!... wonder what all the abstracts can be about... just shows how much science is going on.... excited to get to see the posters